Pharmaceutical Technology Europe-12-01-2008

i2-574640-1408668417386.gif

Pharmaceutical Technology Europe

The closing date for comments to be received by the US Pharmacopeia (USP) for proposed revisions to Chapter <231>, which deals with analysis of heavy metals, is 15 December 2008. The USP has been working towards for approximately 4 years and the task has not been easy.

i2-574639-1408668421502.gif

Pharmaceutical Technology Europe

Hundreds of pharma&#150;biotech deals have been announced during 2008 and many of these probably began at biopartnering conferences. Susan Aldridge examines some of this year's big buyouts and mergers.

i1-571530-1408671293183.jpg

Pharmaceutical Technology Europe

It is a universally acknowledged truth that a biotech start-up in possession of little fortune must be in want of venture capital (VC). Perhaps less well acknowledged, however, is that VC investors operate in a way consistent with being rational economic entities...

Partnership power

Pharmaceutical Technology Europe

TranScrip Partners' Flic Gabbay explains why an approach that provides expertise on an 'as needed basis' is flourishing.

i1-571529-1408671296100.jpg

The Obama effect

Pharmaceutical Technology Europe

...the new administration is not anti-science or even anti-industry. It just wants lower prices.

i1-571528-1408671298876.jpg

Pharmaceutical Technology Europe

You don't have to spend any time in the company of its chairman to see that there is no other Big Pharma company like Servier.